The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Serotonin receptors : their key role in drugs to treat schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,381
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Modulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Self-citationD1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Self-citationSchotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Self-citationDopamine receptor pharmacology
Seeman, P., & Van Tol, H. H. M. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90323-9 · Cited by 956
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Self-citationPompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 881
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Kapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (1997) · Nature · doi:10.1038/385634a0 · Cited by 710
Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
Seeman, P., Chau-Wong, M., Tedesco, J., & Wong, K. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4376 · Cited by 701
Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs
Farde, L. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250087012 · Cited by 692
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Self-citationAraneda, R., & Andrade, R. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90128-b · Cited by 625
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Ruat, M., Traiffort, E., Leurs, R., Tardivel-Lacombe, J., Diaz, J., Arrang, J. M., & Schwartz, J. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8547 · Cited by 617
Catecholamine modulation of prefrontal cortical cognitive function
Arnsten, A. F. T. (1998) · Trends in Cognitive Sciences · doi:10.1016/s1364-6613(98)01240-6 · Cited by 604
Choudhary, M. S., Craigo, S., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592
Self-citationEffect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats
Pycock, C. J., Kerwin, R. W., & Carter, C. J. (1980) · Nature · doi:10.1038/286074a0 · Cited by 549
Jakab, R. L., & Goldman-Rakic, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.735 · Cited by 536
Nordström, A.-L., Farde, L., Wiesel, F.-A., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512
A Novel Augmentation Strategy for Treating Resistant Major Depression
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.131 · Cited by 504
Self-citationAntipsychotic Drugs, Neurotransmitters, and Schizophrenia
CARLSSON, A. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.2.164 · Cited by 498
Celada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09917.2001 · Cited by 497
Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494
Self-citationDopamine as the wind of the psychotic fire: new evidence from brain imaging studies
Laruelle, M., & Abi-Dargham, A. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300405 · Cited by 461
Blier, P., & De Montigny, C. (1987) · Synapse · doi:10.1002/syn.890010511 · Cited by 426
Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism
Reynolds, G. P., Zhang, Z.-J., & Zhang, X.-B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08913-4 · Cited by 412
Lawler, C. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00099-2 · Cited by 408
Moghaddam, B., & Bunney, B. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01230.x · Cited by 402
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.799 · Cited by 397
Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90043-d · Cited by 393
Self-citation5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370
Kuroki, T., Meltzer, H. Y., & Ichikawa, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38019-x · Cited by 351
Self-citationSerotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex
Willins, D. L., Deutch, A. Y., & Roth, B. L. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199709)27:1<79::aid-syn8>3.0.co;2-a · Cited by 345
Martı́n-Ruiz, R., Puig, M. V., Celada, P., Shapiro, D. A., Roth, B. L., Mengod, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09856.2001 · Cited by 339
The role of cognition in vocational functioning in schizophrenia
McGurk, S. R., & Meltzer, H. Y. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00198-x · Cited by 337
Self-citationGobert, A., Rivet, J.-M., Lejeune, F., Newman-Tancredi, A., Adhumeau-Auclair, A., Nicolas, J.-P., Cistarelli, L., Melon, C., & Millan, M. J. (2000) · Synapse · doi:10.1002/(sici)1098-2396(20000601)36:3<205::aid-syn5>3.0.co;2-d · Cited by 336
Association between clozapine response and allelic variation in 5-HT2A receptor gene
Arranz, M. J., Collier, D. A., Sodhi, M., Ball, D., Roberts, G. W., Sham, P., Kerwin, R., Price, J., & Roberts, G. W. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92168-0 · Cited by 333
Sprouse, J. S., & Aghajanian, G. K. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90782-x · Cited by 306
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306
Hoyer, D., Pazos, A., Probst, A., & Palacios, J. M. (1986) · Brain Research · doi:10.1016/0006-8993(86)90903-0 · Cited by 291
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287
Burnet, P. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00053-x · Cited by 286
Kapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 284
Millan, M. J., Dekeyne, A., & Gobert, A. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00078-1 · Cited by 283
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276
Effects of antipsychotic drugs on serotonin receptors.
Meltzer, H. Y., & Nash, J. F. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06671-2 · Cited by 258
Self-citationDi Matteo, V., Di Giovanni, G., Di Mascio, M., & Esposito, E. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00047-7 · Cited by 251
Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors in Major Depression
Ostroff, R. B., & Nelson, J. C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0410 · Cited by 248
Ichikawa, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00312-8 · Cited by 248
Self-citationDawson, L. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00265-2 · Cited by 245
Differential pharmacology of newer antidepressants.
DeVane, C. L. (1998) · PubMed · Cited by 237
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study
Newman-Tancredi, A., Gavaudan, S., Conte, C., Chaput, C., Touzard, M., Verrièle, L., Audinot, V., & Millan, M. J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00483-x · Cited by 227
5-HT2 and D2 dopamine receptor occupancy in the living human brain: A PET study with risperidone
Nyberg, S., Farde, L., Eriksson, L., Halldin, C., & Eriksson, B. (1993) · Psychopharmacology · doi:10.1007/bf02251280 · Cited by 227
The neuropharmacology of serotonin and noradrenaline in depression
Nutt, D. J. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200206001-00002 · Cited by 221
Dopamine receptor binding in the corpus striatum of mammalian brain.
Burt, D. R., Enna, S. J., Creese, I., & Snyder, S. H. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4655 · Cited by 220
Prisco, S., Pagannone, S., & Esposito, E. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22843-9 · Cited by 214
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
Bantick, R. A., Deakin, J. F. W., & Grasby, P. M. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500108 · Cited by 214
Feng, J., Cai, X., Zhao, J., & Yan, Z. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06502.2001 · Cited by 212
5-HT 7 receptors: current knowledge and future prospects
Vanhoenacker, P., Haegeman, G., & Leysen, J. E. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01432-7 · Cited by 209
Sumiyoshi, T., Matsui, M., Nohara, S., Yamashita, I., Kurachi, M., Sumiyoshi, C., Jayathilake, K., & Meltzer, H. Y. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1722 · Cited by 207
Self-citationClozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation
Rollema, H., Lu, Y., Schmidt, A. W., & Zorn, S. H. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)81951-6 · Cited by 203
Kramer, M. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180085011 · Cited by 199
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors.
Roth, B. L., Ciaranello, R. D., & Meltzer, H. Y. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11452-3 · Cited by 197
Self-citationEffects of clozapine on cognitive function in schizophrenia.
Lee, M. A., Thompson, P. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 196
Self-citationIchikawa, J., Li, Z., Dai, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03570-9 · Cited by 196
Self-citationRollema, H., Lu, Y., Schmidt, A. W., Sprouse, J. S., & Zorn, S. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00850-7 · Cited by 195
Two distinct effects of 5-hydroxytryptamine on single cortical neurons
Davies, M. F., Deisz, R. A., Prince, D. A., & Peroutka, S. J. (1987) · Brain Research · doi:10.1016/0006-8993(87)90861-4 · Cited by 195
Sleight, A. J., Boess, F. G., Bös, M., Levet‐Trafit, B., Riemer, C., & Bourson, A. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701851 · Cited by 180
Anthony Altar, C., Wasley, A. M., Neale, R. F., & Stone, G. A. (1986) · Brain Research Bulletin · doi:10.1016/0361-9230(86)90181-4 · Cited by 176
Localization of 5-HT2A receptors on dopamine cells in subnuclei of the midbrain A10 cell group
Nocjar, C., Roth, B. L., & Pehek, E. A. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00593-0 · Cited by 171
Lucas, G., & Spampinato, U. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740693.x · Cited by 170
Gefvert, O., Bergström, M., Långström, B., Lundberg, T., Lindström, L., & Yates, R. (1998) · Psychopharmacology · doi:10.1007/s002130050492 · Cited by 169
Hertel, P., Fagerquist, M. V., & Svensson, T. H. (1999) · Science · doi:10.1126/science.286.5437.105 · Cited by 169
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant
Meltzer, H. Y., Young, M., Metz, J., Fang, V. S., Schyve, P. M., & Arora, R. C. (1979) · Journal of Neural Transmission · doi:10.1007/bf01250091 · Cited by 167
Self-citation5-HT2 Receptor Regulation of Extracellular GABA Levels in the Prefrontal Cortex
Abi-Saab, W. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00046-3 · Cited by 158
Farde, L., Nyberg, S., Oxenstierna, G., Nakashima, Y., Halldin, C., & ERICSSON, B. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00004 · Cited by 157
Duinkerke, S. J., Botter, P. A., Jansen, A. A. I., van Dongen, P. A. M., Haaften, A. J. V., Boom, A. J., Laarhoven, J. H. M. V., & Busard, H. L. S. M. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.4.451 · Cited by 156
5-HT 6 receptor antagonists enhance retention of a water maze task in the rat
Rogers, D., & Hagan, J. J. (2001) · Psychopharmacology · doi:10.1007/s002130100840 · Cited by 155
The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia
Sumiyoshi, T., Matsui, M., Yamashita, I., Nohara, S., Kurachi, M., Uehara, T., Sumiyoshi, S., Sumiyoshi, C., & Meltzer, H. Y. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01025-8 · Cited by 154
Self-citationSerotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients
Arora, R. C., & Meltzer, H. Y. (1991) · Journal of Neural Transmission · doi:10.1007/bf01244654 · Cited by 154
Self-citationLiégeois, J.-F., Ichikawa, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02620-3 · Cited by 145
Self-citationRoth, B. L., Tandra, S., Burgess, L. H., Sibley, D. R., & Meltzer, H. Y. (1995) · Psychopharmacology · doi:10.1007/bf02311185 · Cited by 143
Self-citationSakaue, M., Somboonthum, P., Nishihara, B., Kōyama, Y., Hashimoto, H., Baba, A., & Matsuda, T. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703139 · Cited by 143
In Vivo Resetting of the Hamster Circadian Clock by 5-HT7Receptors in the Suprachiasmatic Nucleus
Ehlen, J. C., Grossman, G. H., & Glass, J. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05351.2001 · Cited by 139
Cai, X., Gu, Z., Zhong, P., Ren, Y., & Yan, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203752200 · Cited by 134
Attenuation of haloperidol‐induced catalepsy by a 5‐HT2C receptor antagonist
Reavill, C. A., Kettle, A., Holland, V. A., Riley, G. J., & Blackburn, T. P. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702350 · Cited by 133
Psychotropic medications in lactation.
Llewellyn, A., & Stowe, Z. N. (1998) · PubMed · Cited by 132
Maurel-Remy, S., Bervoets, K., & Millan, M. J. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00333-g · Cited by 130
Serotonin-6 receptor variant (C267T) and clinical response to clozapine
Yu, Y. W. ‐., Tsai, S., Lin, C., Hsu, C., Yang, K., & Hong, C. (1999) · Neuroreport · doi:10.1097/00001756-199904260-00014 · Cited by 126
Lee, M., Jayathilake, K., & Meltzer, H. Y. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00145-5 · Cited by 120
Self-citationWesterink, B. H. C., Kawahara, Y., Boer, P. D., Geels, C., Vries, J. B. D., Wikström, H., Kalkeren, A. A. V., Vliet, B. J. V., Kruse, C. G., & Long, S. K. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00935-3 · Cited by 120
Rinaldi, M. L., Congy, C., Santucci, V., Simiand, J., Gautret, B., Neliat, G., Labeeuw, B., Fur, G. L., Soubrié, P., & Brelière, J. C. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10821-5 · Cited by 116
Lieberman, J. A. (1993) · British Journal of Psychiatry · doi:10.1192/s0007125000292544 · Cited by 108
Matteo, V. D., Giovanni, G. D., Mascio, M. D., & Esposito, E. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00014-8 · Cited by 107
What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression?
Thase, M. E. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0202 · Cited by 107
Gill, H. S., DeVane, C. L., & Risch, S. C. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00007 · Cited by 107
Wadenberg, M.-L., & Ahlenius, S. (1991) · Journal of Neural Transmission · doi:10.1007/bf01244451 · Cited by 106
Bentley, J., Bourson, A., Boess, F., Fone, K. C. F., Marsden, C. A., Petit, N., & Sleight, A. J. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702445 · Cited by 105
Regulation of GABA release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus
Matsuyama, S., Nei, K., & Tanaka, C. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00318-1 · Cited by 103
Andersson, J. L., Nomikos, G. G., Marcus, M. M., Hertel, P., Mathé, J. M., & Svensson, T. H. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00172774 · Cited by 102
Clozapine and the Dopamine Hypothesis of Schizophrenia, a Critical Appraisal
Bürki, H. R., Eichenberger, E., Sayers, A., & White, T. G. (1975) · Pharmacopsychiatry · doi:10.1055/s-0028-1094449 · Cited by 99
5-ht6 Receptors as Emerging Targets for Drug Discovery
Branchek, T. A., & Blackburn, T. P. (2000) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.319 · Cited by 98
Cai, X., Flores‐Hernandez, J., Feng, J., & Yan, Z. (2002) · The Journal of Physiology · doi:10.1113/jphysiol.2001.013391 · Cited by 97
An open clinical and biochemical study of ritanserin in acute patients with schizophrenia
Wiesel, F., Nordström, A., Farde, L., & Eriksson, B. (1994) · Psychopharmacology · doi:10.1007/bf02245441 · Cited by 95
Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex
Matsubara, S., & Meltzer, H. Y. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90027-1 · Cited by 93
Self-citationMasellis, M., Basile, V. S., Meltzer, H. Y., Lieberman, J. A., Sevy, S. M., Goldman, D. A., Hamblin, M. W., Macciardi, F. M., & Kennedy, J. L. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00016-5 · Cited by 89
Self-citationVolonté, M., Monferini, E., Cerutti, M., Fodritto, F., & Borsini, F. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010182.x · Cited by 88
Ichikawa, J., Kuroki, T., Dai, J., & Meltzer, H. Y. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00308-2 · Cited by 88
Self-citationPhysiological, Pathophysiological and Therapeutic Roles of 5-HT Systems in Learning and Memory
Meneses, A. (1998) · Reviews in the Neurosciences · doi:10.1515/revneuro.1998.9.4.275 · Cited by 83
Sprouse, J. S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00057-3 · Cited by 82
Stephenson, C., Bigliani, V., Jones, H., Mulligan, R. S., Acton, P. D., Visvikis, D., Ell, P. J., Kerwin, R. W., & Pilowsky, L. S. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.408 · Cited by 81
Bonaccorso, S. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00311-1 · Cited by 80
Pehek, E. A., & Yamamoto, B. K. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63062118.x · Cited by 80
Rasmussen, K., & Aghajanian, G. K. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90001-2 · Cited by 76
Bymaster, F. P., & Felder, C. C. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001019 · Cited by 75
Serotonin 5-HT2 Receptors in Schizophrenic Patients Studied by Positron Emission Tomography
Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)80005-3 · Cited by 75
Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression
Ranjan, R., & Meltzer, H. Y. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00305-3 · Cited by 73
Self-citationSesack, S. R., Bressler, C. N., & Lewis, D. A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12076-g · Cited by 71
5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine
Travis, M. J., Busatto, G. F., Pilowsky, L. S., Mulligan, R. S., Acton, P. D., Gacinovic, S., Mertens, J. J. R., Terriere, D., Costa, D. C., Ell, P. J., et al. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.173.3.236 · Cited by 68
Lane, H., Lin, Y., & Chang, W. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0207f · Cited by 67
Basal forebrain glutamatergic modulation of cortical acetylcholine release
Fadel, J. R., Sarter, M. F., & Bruno, J. P. (2001) · Synapse · doi:10.1002/1098-2396(20010301)39:3<201::aid-syn1001>3.0.co;2-3 · Cited by 66
Schoffelmeer, A. N. M., Hogenboom, F., & Mulder, A. H. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701394 · Cited by 66
Millan, M. J., Gobert, A., Newman‐Tancredi, A., Audinot, V., Lejeune, F., Rivet, J., Cussac, D., Nicolas, J., Müller, O., & Lavielle, G. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37731-6 · Cited by 65
High 5HT 2A receptor occupancy in M100907-treated schizophrenic patients
Talvik, M., Nyberg, S., Nordström, A., Ito, H., Halldin, C., Brunner, F., & Farde, L. (2000) · Psychopharmacology · doi:10.1007/s002130050069 · Cited by 61
Chivers, J. K., Gommeren, W., Leysen, J. E., Jenner, P. G., & MARSDEN, C. D. (1988) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1988.tb06306.x · Cited by 59
Nordström, A., Nyberg, S., Olsson, H., & Farde, L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.283 · Cited by 59
Consolo, S., Arnaboldi, S., Ramponi, S., Nannini, L., Ladinsky, H., & Baldi, G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12940-6 · Cited by 56
DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release
Ichikawa, J., Dai, J., & Meltzer, H. Y. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02596-3 · Cited by 56
Self-citationIchikawa, J., Dai, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02544-1 · Cited by 55
Self-citationAssié, M., Cosi, C., & Koek, W. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01207-7 · Cited by 55
Wettstein, J. G., Host, M., & Hitchcock, J. M. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(99)00014-7 · Cited by 52
Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain
Frederick, J. A., & Meador‐Woodruff, J. H. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00002-x · Cited by 52
Wadenberg, M.-L., Hertel, P., Fernholm, R., Blakeman, K. H., Ahlenius, S., & Svensson, T. H. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070036 · Cited by 51
Wadenberg, M.-L., Salmi, P., Jimenez, P., Svensson, T. H., & Ahlénius, S. (1996) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00035-1 · Cited by 50
Garraway, S. M., & Hochman, S. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703983 · Cited by 48
Hirose, A., Sasa, M., AKAIKE, A., & Takaori, S. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90048-v · Cited by 47
Further evidence for clozapine as a dopamine D1 receptor agonist
Salmi, P., & Ahlénius, S. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00181-1 · Cited by 47
The Importance of Dopamine D4 Receptors in the Action and Development of Antipsychotic Agents
Reynolds, G. P. (1996) · Drugs · doi:10.2165/00003495-199651010-00002 · Cited by 46
Increasing D2 affinity results in the loss of clozapineʼs atypical antipsychotic action
Kapur, S., MCCLELLAND, R. A., VanderSpek, S. C., Wadenberg, M.-L. G., Baker, G. B., Nóbrega, J. N., Zipursky, R. B., & Seeman, P. M. (2002) · Neuroreport · doi:10.1097/00001756-200205070-00019 · Cited by 41
Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
Purdon, S. E. (2000) · PubMed · Cited by 39
Cozzi, N. V., & Nichols, D. E. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00325-1 · Cited by 38
Yamaguchi, T., Suzuki, M., & Yamamoto, M. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005110 · Cited by 37
Nakai, K., Fujii, T., Fujimoto, K., Suzuki, T., & Kawashima, K. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00019-4 · Cited by 33
Lack of acute antipsychotic effect of Sch 23390, a selective dopamine D1 receptor antagonist
Gessa, G., Canu, A., Zompo, M. D., Burrai, C., & Serra, G. (1991) · The Lancet · doi:10.1016/0140-6736(91)92565-j · Cited by 31
Pharmacological therapy of dysthymia
Lapierre, Y. D. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05882.x · Cited by 30
VanderMaelen, C. P., & Braselton, J. P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90176-7 · Cited by 29
Yamaguchi, T., Suzuki, M., & Yamamoto, M. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00856-1 · Cited by 27
Aripiprazole (Otsuka Pharmaceutical Co).
Özdemir, V., Fourie, J., & Özdener, F. (2002) · PubMed · Cited by 27
Rowley, H. L., Needham, P. L., Kilpatrick, I. C., & Heal, D. J. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900170 · Cited by 26
Materi, L. M., & Semba, K. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01619.x · Cited by 26
Marcus, M. M., Malmerfelt, A., Nyberg, S., & Svensson, T. H. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00048-2 · Cited by 17
The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus
Antoniou, K. M., Bekris, S., Saranti, M., Stathis, P. G., Rimikis, M., & Papadopoulou‐Daifotis, Z. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00087-0 · Cited by 10
Cited by
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300542 · Cited by 769
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
Alex, K. D., & Pehek, E. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Metadata
- Authors
- Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 27
- Issue
- 7
- Pages
- 1159-1172
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2095213614
- Cited by
- 775
- References
- 167
- FWCI
- 25.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.